Hydrogels for brain repair: application to Parkinson's disease.

Parkinson’s disease cell transplantation drug delivery hydrogels neurotrophic factors pluripotent stem cells protein therapy rheological properties

Journal

Expert opinion on drug delivery
ISSN: 1744-7593
Titre abrégé: Expert Opin Drug Deliv
Pays: England
ID NLM: 101228421

Informations de publication

Date de publication:
11 2022
Historique:
pubmed: 15 10 2022
medline: 9 11 2022
entrez: 14 10 2022
Statut: ppublish

Résumé

Parkinson's disease is the second most common neurodegenerative disease. Currently, there are no curative therapies, with only symptomatic treatment available. One of the principal reasons for the lack of treatments is the problem of delivering drugs to the brain, mainly due to the blood-brain barrier. Hydrogels are presented as ideal platforms for delivering treatments to the brain ranging from small molecules to cell replacement therapies. The potential application of hydrogel-based therapies for Parkinson's disease is addressed. The desirable composition and mechanical properties of these therapies for brain application are discussed, alongside the preclinical research available with hydrogels in Parkinson's disease. Lastly, translational and manufacturing challenges are presented. Parkinson's disease urgently needs novel therapies to delay its progression and for advanced stages, at which conventional therapies fail to control motor symptoms. Neurotrophic factor-loaded hydrogels with stem cells offer one of the most promising therapies. This approach may increase the striatal dopamine content while protecting and promoting the differentiation of stem cells although the generation of synapses between engrafted and host cells remains an issue to overcome. Other challenges to consider are related to the route of administration of hydrogels and their large-scale production, required to accelerate their translation toward the clinic.

Identifiants

pubmed: 36240170
doi: 10.1080/17425247.2022.2136161
doi:

Substances chimiques

Hydrogels 0
Dopamine VTD58H1Z2X

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1521-1537

Auteurs

Rubén Del Campo-Montoya (R)

Department of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain.
Navarra Institute for Health Research, IdiSNA, Pamplona, Spain.

María-Rosario Luquin (MR)

Navarra Institute for Health Research, IdiSNA, Pamplona, Spain.
Department of Neurology and Neurosciences Clínica Universidad de Navarra, Pamplona Spain.

Elena Puerta (E)

Navarra Institute for Health Research, IdiSNA, Pamplona, Spain.
Department of Pharmacology and Toxicology, Faculty of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain.

Elisa Garbayo (E)

Department of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain.
Navarra Institute for Health Research, IdiSNA, Pamplona, Spain.

María J Blanco-Prieto (MJ)

Department of Pharmaceutical Technology and Chemistry, Faculty of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain.
Navarra Institute for Health Research, IdiSNA, Pamplona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH